Introduction:Intravenous tissue plasminogen activator(IV tPA)is a globally recommended treatment for patients with acute ischaemic stroke.We examined IV tPA use among patients aged 18–64 years with a primary diagnosi...Introduction:Intravenous tissue plasminogen activator(IV tPA)is a globally recommended treatment for patients with acute ischaemic stroke.We examined IV tPA use among patients aged 18–64 years with a primary diagnosis of acute ischaemic stroke in the USA and inpatient costs per hospitalisation by IV tPA use status among these patients.Methods:Using the 2010–2013 MarketScan Commercial Claims and Encounters Inpatient Data,we identified 39149 hospitalisations with a primary diagnosis of acute ischaemic stroke.We verified those with and without IV tPA by ICD-9 procedure code 99.10.We estimated trends in IV tPA use by applying logistic regression.The average inpatient costs per acute ischaemic stroke hospitalisation were assessed for subpopulations.We examined costs per acute ischaemic stroke hospitalisation using multivariate regression models controlling for IV tPA status,age,gender,urbanisation,geographic region,Charlson comorbidity index,length of hospital stays(LOS)and discharge status.Results:2546 hospitalisations(6.5%)used IV tPA.IV tPA use increased over time(2010 vs 2013;OR 1.50).Average inpatient costs per acute ischaemic stroke hospitalisation were$20331($31369 for the IV tPA group,$19563 for the non-tPA group).From multivariate analyses,higher costs per acute ischaemic stroke hospitalisation were associated with longer LOS,non-home discharge destination,and IV tPA use,which might be correlated with severity of stroke.Conclusions:Findings suggest that IV tPA use has increased in recent years while the inpatient costs per acute ischaemic stroke hospitalisation using IV tPA are substantial.Those findings are useful in better understanding the overall economic burden of stroke,short-term cost implications of using IV tPA,and for estimating the accurate cost-effectiveness of stroke treatments.展开更多
Forty years ago,smallpox was declared eradicated by the World Health Organization(WHO).As D.A.Henderson,Director of the Smallpox Eradication Programme at the WHO quoted from the 33^(rd) World Health Assembly(1980)(1),...Forty years ago,smallpox was declared eradicated by the World Health Organization(WHO).As D.A.Henderson,Director of the Smallpox Eradication Programme at the WHO quoted from the 33^(rd) World Health Assembly(1980)(1),“...the world and all its peoples have won freedom from smallpox...a most devastating disease...since earliest time,leaving death,blindness,and disfigurement in its wake and which only a decade ago was rampant in Africa,Asia and South America.”展开更多
Congratulations to China CDC on the launch of the China CDC Weekly.Through timely,accurate reporting on public health surveillance,epidemiologic investigations,and emergency responses,and by sharing lessons learned an...Congratulations to China CDC on the launch of the China CDC Weekly.Through timely,accurate reporting on public health surveillance,epidemiologic investigations,and emergency responses,and by sharing lessons learned and evidence-based recommendations for public health practice,this new publication will contribute to improving public health.展开更多
2014年6月13日,美国加利福尼亚州公共卫生部（California Department of Public Health,CDPH）接到该州百日咳发病率已超过基线水平5倍的报告,随即宣布该州出现百日咳疫情。美国的百日咳发病存在周期性,随着易感人群的增加,每3~5年出现...2014年6月13日,美国加利福尼亚州公共卫生部（California Department of Public Health,CDPH）接到该州百日咳发病率已超过基线水平5倍的报告,随即宣布该州出现百日咳疫情。美国的百日咳发病存在周期性,随着易感人群的增加,每3~5年出现一个发病高峰。展开更多
过去,生活在福利机构的智障人群中发生甲型肝炎（甲肝）病毒（Hepatitis A Virus,HAV）感染较为常见。随着护理水平的提高和在福利机构中生活的人越来越少,这些机构中发生HAV感染的次数有所下降。但如果生活在福利机构中的人未接种过甲...过去,生活在福利机构的智障人群中发生甲型肝炎（甲肝）病毒（Hepatitis A Virus,HAV）感染较为常见。随着护理水平的提高和在福利机构中生活的人越来越少,这些机构中发生HAV感染的次数有所下降。但如果生活在福利机构中的人未接种过甲肝疫苗（Hepatitis A Vaccine,Hep A）,他们对HAV仍然是易感的。展开更多
2014年10月,美国免疫实施咨询委员会（Advisory Committee on Immunization Practices,ACIP）批准了2015年美国推荐的≥19岁成人免疫程序。本免疫程序提供美国ACIP推荐疫苗的使用建议,包含了疫苗的两个免疫程序表格、脚注,一个描述主要...2014年10月,美国免疫实施咨询委员会（Advisory Committee on Immunization Practices,ACIP）批准了2015年美国推荐的≥19岁成人免疫程序。本免疫程序提供美国ACIP推荐疫苗的使用建议,包含了疫苗的两个免疫程序表格、脚注,一个描述主要禁忌证和慎用证的表格。展开更多
文摘Introduction:Intravenous tissue plasminogen activator(IV tPA)is a globally recommended treatment for patients with acute ischaemic stroke.We examined IV tPA use among patients aged 18–64 years with a primary diagnosis of acute ischaemic stroke in the USA and inpatient costs per hospitalisation by IV tPA use status among these patients.Methods:Using the 2010–2013 MarketScan Commercial Claims and Encounters Inpatient Data,we identified 39149 hospitalisations with a primary diagnosis of acute ischaemic stroke.We verified those with and without IV tPA by ICD-9 procedure code 99.10.We estimated trends in IV tPA use by applying logistic regression.The average inpatient costs per acute ischaemic stroke hospitalisation were assessed for subpopulations.We examined costs per acute ischaemic stroke hospitalisation using multivariate regression models controlling for IV tPA status,age,gender,urbanisation,geographic region,Charlson comorbidity index,length of hospital stays(LOS)and discharge status.Results:2546 hospitalisations(6.5%)used IV tPA.IV tPA use increased over time(2010 vs 2013;OR 1.50).Average inpatient costs per acute ischaemic stroke hospitalisation were$20331($31369 for the IV tPA group,$19563 for the non-tPA group).From multivariate analyses,higher costs per acute ischaemic stroke hospitalisation were associated with longer LOS,non-home discharge destination,and IV tPA use,which might be correlated with severity of stroke.Conclusions:Findings suggest that IV tPA use has increased in recent years while the inpatient costs per acute ischaemic stroke hospitalisation using IV tPA are substantial.Those findings are useful in better understanding the overall economic burden of stroke,short-term cost implications of using IV tPA,and for estimating the accurate cost-effectiveness of stroke treatments.
文摘Forty years ago,smallpox was declared eradicated by the World Health Organization(WHO).As D.A.Henderson,Director of the Smallpox Eradication Programme at the WHO quoted from the 33^(rd) World Health Assembly(1980)(1),“...the world and all its peoples have won freedom from smallpox...a most devastating disease...since earliest time,leaving death,blindness,and disfigurement in its wake and which only a decade ago was rampant in Africa,Asia and South America.”
文摘Congratulations to China CDC on the launch of the China CDC Weekly.Through timely,accurate reporting on public health surveillance,epidemiologic investigations,and emergency responses,and by sharing lessons learned and evidence-based recommendations for public health practice,this new publication will contribute to improving public health.
文摘过去,生活在福利机构的智障人群中发生甲型肝炎（甲肝）病毒（Hepatitis A Virus,HAV）感染较为常见。随着护理水平的提高和在福利机构中生活的人越来越少,这些机构中发生HAV感染的次数有所下降。但如果生活在福利机构中的人未接种过甲肝疫苗（Hepatitis A Vaccine,Hep A）,他们对HAV仍然是易感的。
文摘2014年10月,美国免疫实施咨询委员会（Advisory Committee on Immunization Practices,ACIP）批准了2015年美国推荐的≥19岁成人免疫程序。本免疫程序提供美国ACIP推荐疫苗的使用建议,包含了疫苗的两个免疫程序表格、脚注,一个描述主要禁忌证和慎用证的表格。
